Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 3
2004 4
2005 7
2006 10
2007 11
2008 11
2009 6
2010 8
2011 9
2012 18
2013 14
2014 14
2015 18
2016 15
2017 14
2018 21
2019 18
2020 17
2021 14
2022 16
2023 21
2024 18
2025 25
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

285 results

Results by year

Filters applied: . Clear all
Page 1
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, Ge J, Weerakkody GJ, Ou Y, Bunck MC, Hurt KC, Murakami M, Borlaug BA; SUMMIT Trial Study Group. Packer M, et al. Among authors: kramer cm. N Engl J Med. 2025 Jan 30;392(5):427-437. doi: 10.1056/NEJMoa2410027. Epub 2024 Nov 16. N Engl J Med. 2025. PMID: 39555826 Clinical Trial.
Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity.
Harper AR, Goel A, Grace C, Thomson KL, Petersen SE, Xu X, Waring A, Ormondroyd E, Kramer CM, Ho CY, Neubauer S; HCMR Investigators; Tadros R, Ware JS, Bezzina CR, Farrall M, Watkins H. Harper AR, et al. Among authors: kramer cm. Nat Genet. 2021 Feb;53(2):135-142. doi: 10.1038/s41588-020-00764-0. Epub 2021 Jan 25. Nat Genet. 2021. PMID: 33495597 Free PMC article.
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4.
Masri A, Sherrid MV, Abraham TP, Choudhury L, Garcia-Pavia P, Kramer CM, Barriales-Villa R, Owens AT, Rader F, Nagueh SF, Olivotto I, Saberi S, Tower-Rader A, Wong TC, Coats CJ, Watkins H, Fifer MA, Solomon SD, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Meng L, Sohn RL, Wohltman A, Maron MS; REDWOOD-HCM Investigators. Masri A, et al. Among authors: kramer cm. J Card Fail. 2024 Nov;30(11):1439-1448. doi: 10.1016/j.cardfail.2024.02.020. Epub 2024 Mar 15. J Card Fail. 2024. PMID: 38493832 Free article. Clinical Trial.
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy.
Maron MS, Masri A, Choudhury L, Olivotto I, Saberi S, Wang A, Garcia-Pavia P, Lakdawala NK, Nagueh SF, Rader F, Tower-Rader A, Turer AT, Coats C, Fifer MA, Owens A, Solomon SD, Watkins H, Barriales-Villa R, Kramer CM, Wong TC, Paige SL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Abraham T; REDWOOD-HCM Steering Committee and Investigators. Maron MS, et al. Among authors: kramer cm. J Am Coll Cardiol. 2023 Jan 3;81(1):34-45. doi: 10.1016/j.jacc.2022.10.020. J Am Coll Cardiol. 2023. PMID: 36599608 Free article. Clinical Trial.
Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM Cardiac Magnetic Resonance Substudy Analysis.
Saberi S, Cardim N, Yamani M, Schulz-Menger J, Li W, Florea V, Sehnert AJ, Kwong RY, Jerosch-Herold M, Masri A, Owens A, Lakdawala NK, Kramer CM, Sherrid M, Seidler T, Wang A, Sedaghat-Hamedani F, Meder B, Havakuk O, Jacoby D. Saberi S, et al. Among authors: kramer cm. Circulation. 2021 Feb 9;143(6):606-608. doi: 10.1161/CIRCULATIONAHA.120.052359. Epub 2020 Nov 15. Circulation. 2021. PMID: 33190524 No abstract available.
Demographic-Based Personalized Left Ventricular Hypertrophy Thresholds for Hypertrophic Cardiomyopathy Diagnosis.
Shiwani H, Davies RH, Topriceanu CC, Ditaranto R, Owens A, Raman B, Augusto J, Hughes RK, Torlasco C, Dowsing B, Artico J, Joy G, Miranda I, Witschey W, Rodriguez-Palomares JF, Badia-Molins C, Crotti L, Cortina-Borja M, Chuang ML, Kwong RY, Kramer CM, Manning W, Ho CY, Kellman P, Hughes AD, Biagini E, Mohiddin S, Lopes L, Litt H, Ferrari VA, Captur G, Moon JC; PRECISION-HCM Collaborative. Shiwani H, et al. Among authors: kramer cm. J Am Coll Cardiol. 2025 Feb 25;85(7):685-695. doi: 10.1016/j.jacc.2024.10.082. Epub 2025 Jan 8. J Am Coll Cardiol. 2025. PMID: 39772357 Free PMC article.
Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy.
Masri A, Cardoso RN, Abraham TP, Claggett BL, Coats CJ, Hegde SM, Kulac IJ, Lee MMY, Maron MS, Merkely B, Michels M, Olivotto I, Oreziak A, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Solomon SD, Wohltman A, Kwong RY, Kramer CM; SEQUOIA-HCM Investigators. Masri A, et al. Among authors: kramer cm. J Am Coll Cardiol. 2024 Nov 5;84(19):1806-1817. doi: 10.1016/j.jacc.2024.08.015. Epub 2024 Sep 1. J Am Coll Cardiol. 2024. PMID: 39217563 Free article. Clinical Trial.
285 results